Advanced Biomed Inc
advanbiomed.comAdvanced Biomed Inc (ADVB) is a pre-revenue medical device company developing liquid biopsy and cancer detection products for regulatory clearance and commercial sale in China. The company has not generated product revenue as of the fiscal year ended June 30, 2025, and has funded operations through its IPO, which raised gross proceeds of $6.56 million at $4.00 per share, and an equity line of credit agreement with Helena Global Investment Opportunities I Ltd. signed June 6, 2025. Advanced Biomed reported net losses of $3,258,969 and $2,782,278 for the fiscal years ended June 30, 2025 and June 30, 2024, respectively, with the auditors raising going concern doubt. The company operates in Taiwan and China, and its products require clearance from China's National Medical Products Administration before commercial sale. Two products, A+Pre and AC-1000, have received NMPA clearance; additional products remain in registration or clinical trial stages.
Products & Services
Advanced Biomed's product portfolio consists of liquid biopsy devices and associated microfluidic chips for cancer detection. A+Pre and AC-1000 (including their corresponding chips) have received NMPA clearance. A+SCDrop, A+CellScan, A+CellScan Chip, and A+LCGuard are at the NMPA registration application stage. Four matching immunostaining kits are under NMPA registration review. A+LCGuard is a Class III medical device requiring clinical trials before registration completion. In May 2023 pre-mass production testing, A+Pre chips achieved an average tumor cell recovery rate of 94% and AC-1000 chips achieved an average recovery rate of 79.5%.
Revenue Model
No product revenue has been disclosed in the 10-K filed 2025-10-08. The company is pre-commercial, funding operations through equity issuances including a completed IPO and an equity line of credit. Revenue is contingent on NMPA regulatory clearance and commercialization of its medical device products.
Customers & Markets
End markets are oncology diagnostics and cancer screening in China. The company conducted 123 case studies at Shanghai Pulmonary Hospital between July 17, 2019 and December 2021, testing A+Pre, AC-1000, and A+LCGuard. No commercial customers are disclosed in the filing.
Geographic Exposure
Operations span Taiwan and China. Products are being registered with China's NMPA. The company notes regulatory and investment restrictions applicable to Taiwanese shareholders investing in China under Taiwan's Permission Regulations. No other jurisdictions are named as active markets as of the filing date.
Source: SEC 10-K, filed 2025-10-08
Financial Snapshot
Loading...
